New drug TALZENNA tested for Tough-to-Treat breast cancer
NCT ID NCT06735742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety of the drug TALZENNA in people with a specific type of breast cancer (BRCA mutation-positive, HER2-negative) that cannot be surgically removed or has come back after previous chemotherapy. Only 3 participants who have not used TALZENNA before will receive the drug as prescribed and be followed for up to 12 months. The main goal is to track any side effects, especially those affecting the bone marrow, lungs, blood vessels, or causing new tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan